Clinical Trials Logo

Filter by:
NCT ID: NCT00928317 Terminated - Clinical trials for Rheumatoid Arthritis

Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate

Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to assess the safety, efficacy, tolerability, immunogenicity and pharmacokinetics of 3 dose levels of ART621 in the treatment of rheumatoid arthritis.

NCT ID: NCT00900146 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Start date: April 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.

NCT ID: NCT00895895 Terminated - Alzheimer Disease Clinical Trials

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Subjects who receive placebo for period I will be assigned to receive the highest dose of SAM-531 SAM-531 for the remaining 28 weeks of the study, while subjects who received one of the three SAM-531 dosage levels or donepezil in period I will continue with the same study drug (period II).

NCT ID: NCT00886769 Terminated - Clinical trials for Systemic Juvenile Idiopathic Arthritis

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

ß-SPECIFIC 1
Start date: July 2009
Phase: Phase 3
Study type: Interventional

This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare. Response to treatment will be according to the adapted American College of Rheumatology(ACR)Pediatric 30 criteria at Day 15.

NCT ID: NCT00883116 Terminated - Endometrial Cancer Clinical Trials

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

IXAMPLE2
Start date: August 2009
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.

NCT ID: NCT00879970 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Thiazolidinedione Intervention With Vitamin D Evaluation

TIDE
Start date: May 2009
Phase: Phase 4
Study type: Interventional

This study will answer two separate questions. The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard of care without rosiglitazone or pioglitazone in patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease. The second question will compare the effects of long-term supplementation of vitamin D on death and cancer

NCT ID: NCT00865592 Terminated - Type 2 Diabetes Clinical Trials

Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.

NCT ID: NCT00858364 Terminated - Cancer Clinical Trials

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Start date: July 17, 2009
Phase: Phase 3
Study type: Interventional

This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC). The primary objective of the study is to demonstrate that overall survival (OS) is not worse in participants on darbepoetin alfa treated to a hemoglobin ceiling of 12.0 g/dL compared to participants treated with placebo.

NCT ID: NCT00850239 Terminated - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

Start date: May 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the efficacy of dutogliptin over 26 weeks (as evidenced by placebo-corrected changes in HbA1c relative to baseline), to demonstrate safety and tolerability of dutogliptin, and to demonstrate changes in fasting plasma glucose over 26 weeks.

NCT ID: NCT00849667 Terminated - Ovarian Cancer Clinical Trials

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Start date: April 16, 2009
Phase: Phase 3
Study type: Interventional

This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.